Does atenolol differ from other β-adrenergic blockers?

BMC Clinical Pharmacology

Volumn 7, Issue , 2007, Pages

  Aursnes, Ivar ^a   Osnes, Jan Bjørn ^a   Tvete, Ingunn Fride ^a   Gåsemyr, Jørund ^a   Natvig, Bent ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PLACEBO;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BAYES THEOREM; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LONG TERM CARE; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; COMPARATIVE STUDY; META ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; BAYES THEOREM; HUMANS; HYPERTENSION; META-ANALYSIS; MYOCARDIAL INFARCTION;

EID: 34249044533     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-7-4     Document Type: Article

References (9)

1. Lindholm LH Carlberg B Samuelsson O Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 2005 366 1545-53 10.1016/S0140-6736(05)67573-3 16257341
2. Holme I MAPHY and the two arms of HAPPHY JAMA 1989 262 3272-3274 10.1001/ jama.262.23.3272 2573740
3. Åblad B Bjurö T Björkman J-A Edström T Olsson G Role of central nervous β-adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone J Am Coll Cardiol 1991 17 1A-65 1988487
4. Christensen KL Mulvany MJ Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: A literature survey Journal of Hypertension 2001 19 1001-6 10.1097/ 00004872-200106000-00002 11403346
5. Freemantle N Cleland J Young P Mason J Harrison J β blockade after myocardial infarction: Systematic review and meta regression analysis BMJ 1999 318 1730-7 31101 10381708
6. Aursnes I Tvete IF Gåsemyr J Natvig B Clinical efficacies of antihypertensive drugs Scand Cardiovasc J 2003 37 72-9 10.1080/ 14017430310001186 12775305
7. Carlberg B Samuelsson O Lindholm LH Atenolol in hypertension: Is it a wise choice? Lancet 2004 364 1684-89 10.1016/S0140-6736(04)17355-8 15530629
8. Wilkinson IB McEniery CM Cockroft JR Atenolol and cardiovascular risk: an issue close to the heart Lancet 2006 367 627-9 10.1016/ S0140-6736(06)68238-X 16503444
9. Beevers DG The end of β blockers for uncomplicated hypertension? Lancet 2005 366 1510-2 10.1016/S0140-6736(05)67575-7 16257329